Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Authors
Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
Heather L. McArthur (ORCID: https://orcid.org/0000-0002-0201-3871)
Sherene Loi (ORCID: https://orcid.org/0000-0001-6137-9171)
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Giuseppe Curigliano, Heather L. McArthur, Sherene Loi, Aparna Chhibber et al.
Journal
Future Oncology
Topics
Breast Cancer Treatment Studies
article
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Giuseppe Curigliano, Heather L. McArthur, Sherene Loi, Aparna Chhibber, Roberto Salgado, Lajos Pusztai, Denise A. Yardley, Nadia Harbeck, Elizabeth A. Mittendorf, Valentina Guarneri, Thomas Spires, Daniel Egle, Raheel Nathani, Misena Pacius, Alberto Suárez Zaizar, Marleen Kok, Andrei Ungureanu, Cristina Saura, Suzette Delaloge, Jenny Wu, Felipe Ades, Carlos Ignacio Rojas García, Rajalakshmi Chandra, Roberto Iván Romero Díaz, Facundo Rufino Caminos, Joaquin G. Reinoso-Toledo
article en
Abstract
No abstract available for this paper.
Publication Tag
Future OncologyVol. 21(24)
Institutions
Hebron University (PS), University of Padua (IT), Innsbruck Medical University (AT), The University of Melbourne (AU), Instituto Tecnológico de Oaxaca (MX), University of Milan (IT), Dutch Cancer Society (NL), Peter MacCallum Cancer Centre (AU), Institut Gustave Roussy (FR), Physiotherapy New Zealand (NZ), Sarah Cannon (US), Antwerp University Hospital (BE), Istituto Oncologico Veneto (IT), MSD (Mexico) (MX), Vall d'Hebron Hospital Universitari (ES), Bristol-Myers Squibb (Sweden) (SE), Tennessee Oncology (US), Clinica Santa Maria (CL), Servicio Diabetología Hospital Córdoba (AR), Mylan (Switzerland) (CH), Universidad Interamericana del Norte (MX), Austrian Breast & Colorectal Cancer Study Group (AT), Dana-Farber Brigham Cancer Center (US), Smilow Cancer Hospital (US), European Institute of Oncology (IT), Ludwig-Maximilians-Universität München (DE), The University of Texas Southwestern Medical Center (US)